claudication in her lower limbs. Her exercise tolerance was limited to 50 metres over the past 2 months and she had rest pain. Other symptoms included widespread musculoskeletal pain, chest pain, headaches and jaw pain on mastication. Lower limb Doppler ultrasound demonstrated significant stenosis of the distal femoral arteries bilaterally with hypoechoic haloes typical for vasculitis. Immunology tests were all negative but inflammatory markers were raised (ESR 43 mm/h, CRP 14 mg/L). In view of the Doppler findings and GCA symptoms she was started on prednisolone 60mg. The prednisolone was held 2 days before a PET-CT which demonstrated mild uptake in both femoral arteries with no evidence of aortitis.Her CT angiogram showed significant diffuse atheromatous disease in the superficial femoral and popliteal arteries bilaterally. In view of this, the PET-CT uptake was thought to be in keeping with atherosclerosis rather than vasculitis. Her prednisolone was therefore stopped and she was transferred to a tertiary vascular centre for further management. The vascular team at our hospital were still concerned about the possibility of vasculitis and a second rheumatology opinion was sought. Her inflammatory markers continued to rise (ESR 76 mm/h, CRP 29 mg/L). It was felt that the PET-CT results may have been affected by high-dose prednisolone which was temporarily held. The PET-CT was therefore repeated having been off steroids for 4 weeks. This demonstrated increased uptake in the superficial femoral and profunda arteries when compared to her previous scan. All her images were reviewed and the diagnosis was felt to be in keeping with LVV. Furthermore, she had a good clinical response to 40mg prednisolone and methotrexate was subsequently added. Discussion: Classical GCA typically presents with cranial symptoms. Extracranial symptoms such claudication can occur although only 4% of patients fall into this category. In our patient, femoral arteritis presented with lower limb claudication. Peripheral limb ischaemia and/or aorta involvement is associated with a slightly younger demographic of LVV (<60years). Initially, there was diagnostic uncertainty given her raised inflammatory markers and hypoechoic femoral artery haloes on Doppler ultrasound, yet diffuse atherosclerosis on the CT angiogram. Hypoechoic haloes and multiple short segment occlusions are more typically seen in vasculitis rather than atherosclerotic disease. Accelerated atherosclerosis is common in primary vasculitides. Despite establishing the diagnosis of LVV by ultrasound in this case, the sensitivity for this in the common femoral artery is < 17%, and PET-CT is preferred. EULAR recommendations for LVV diagnosis include ultrasound and PET-CT. PET-CT was performed twice in this patient because the initial scan was performed following temporary cessation of high-dose steroids, which can decrease the sensitivity of PET-CT. The first PET-CT showed only mild uptake in the femoral arteries which could be consistent with atherosclerosis. Interestingly, PET-CT has been used to identify plaques vulnerable to rupture bed on FDG-avidity. Recent studies have utilised PET-CT to quantify the burden of atherosclerotic disease to help risk stratify patients accurately. This potential diagnostic ambiguity between vasculitis and atherosclerosis on PET-CT reinforces the importance of remaining off steroids around the time of PET imaging wherepossible. Key learning points: This case sheds light on LVV through several interesting perspectives. Firstly, it is unusual for LVV to present with claudication in the lower limbs in the absence of aortitis, demonstrating the variety of ways in which the same pathophysiological mechanism can present clinically. We also highlight the initial diagnostic challenge, as mild uptake in the femoral arteries on PET-CT can be consistent with atherosclerosis. However, with typical findings of hypoechoic haloes on Doppler ultrasound and raised inflammatory markers, clinically this was in keeping with LVV. Interestingly, a repeat PET-CT off steroids demonstrated increased FDG-avidity in the affected areas. This is important as even holding steroids for 2 days before a PET-CT affected the results of the study. This case adds to the growing number of atypical extracranial presentationsof LVV and provides useful insight for future possible cases. Conflict of interest: The authors declare no conflicts of interest.
A CASE OF GIANT CELL ARTERITIS (GCA) CO-EXISTENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)/RHEUMATOID ARTHRITIS (RA) OVERLAP SYNDROME
Matthew Steward 1 , Wah Phin Lee 1 , Anushka Ediriweera 1 , and Ognjenka Savanovic-Abel 1 1 Rheumatology, University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom Introduction: The diagnosis of GCA is relatively straightforward. However, the diagnosis of GCA can be more challenging in the context of complicated SLE and RA in part due to the rarity of the combination of autoimmune disorders. To our knowledge, it is rarely reported in the literature. This case highlights the pitfalls of diagnosis and the added complexities and difficulties in diagnosing GCA in the context of SLE/RA overlap syndrome. Case description: We present a 74-year-old lady with SLE/RA overlap syndrome (RF/ANA & anti-Ro positive) with a medical background of lupus nephritis(WHO grade III), atrial fibrillation and hypothyroidism. She was in clinical remission from RA/SLE whilst on hydroxychloroquine and a yearly rituximab infusion. She then re-presented with a four-week history of fronto-temporal headache progressing to scalp tenderness and pain waking her from sleep. She denied visual symptoms or jaw claudication and there were no features of active lupus or RA. Her C-reactive protein was 62. She was assessed at the rheumatology clinic one week after commencement of prednisolone (40mg) by her GP, with some improvement of symptoms and referred for temporal artery biopsy (TAB) which was negative. By then her symptom improvement with steroid was not consistent. CT head was arranged which showed features that could be related toneuro-lupus. As a result, prednisolone was weaned off quickly. In the next few months, she suffered joint flares and constitutional symptoms despite rituximab and was started on mycophenolate. She also had visual symptoms which were contributed to cataract by the ophthalmologist. Her RA and SLE responded to mycophenolate, but her headache persisted with a further CRP rise to 100 in the absence of RA/SLE features. In this instance, ultrasound demonstrated the 'halo effect' in axillary artery on left. She was referred for a repeat TAB which revealed florid GCA findings histologically and was restarted on60mg prednisolone. During further reduction of her steroid she was re-admitted 6 months later with new neurological symptoms in keeping with an acute stroke. Her MRIheaddemonstrated multipleinfarctspossiblyrelated either tovasculitis or embolic source. However CT angiogram concluded atheromatous changes as opposed to vasculitic. CRP was 10. At present she remains in clinical remissionwith a moderately elevated CRP. Discussion: GCA is diagnosed on the basis of clinical features, laboratory features and positive histology on TAB. Temporal headache, visual symptoms, jaw claudication characterise the GCA, and persistent severe headache can be a manifestation of cerebral lupus in patient who has the diagnosis of SLE. Therefore, in this case, the histological confirmation was essential in the diagnosis of GCA. Even though negative biopsy was discouraging at first, her persistent headache along with further rising of CRP ledustorepeatbiopsyonthecontralateralsidewhichwaspositive,confirmingthediagnosis ofGCA. Temporalartery biopsycouldbe negativeanestimated 15-20% of cases, often due to length of biopsy sample, skip lesions and use of steroids pre-biopsy. There is up to a 5% chance of the contrala-teralbiopsybeingpositivewhenthefirstbiopsywasnegativeforGCA. SLE/RA overlap syndrome is uncommon with an estimated prevalence of between 1-2% of patients with lupus and a general prevalence of around 0.09%. Patients have a tendency towards RA symptoms with typically less SLE features. This case posed diagnostic uncertainty given the persistent features of headache and variable CRP following reduction in steroid therapy, all of which could have been related to symptoms of SLE/RA rather than GCA. Persistently raised inflammatory markers in a scenario with an overlap of 3 inflammatory diseases make unpicking clinical features and an approach to management much more complex in regard to making treatment decisions. There is no data available to guide the management of GCA in these patients. Key learning points: GCA has a heterogeneous clinical presentation which may be complicated by concurrent auto-immune disease and the features of the conditions could overlap. One negative TAB should not discourage performing repeat TAB in this instance if there is high degree of clinical suspicion. Temporal artery biopsy is commonly negative and there is a growing role for the use of ultrasound in the diagnosis of GCA, thecombinationof thesetwoinvestigations couldincrease thediagnostic yield. Place ofPET CTorMRangiogram in diagnosisof GCA inthiscontext should be considered. In the presence of persistently high CRP without clinical evidence of active flare could indicate subclinical inflammation, the approach to which is uncertain. Tocilizumab is licensed for rheumatoid arthritis and recently gained alicense for treatment of giant cell arteritis; however there is no sufficient evidence on efficacy and safety in lupus although there is promising outcome from a phase one open label trial. Conflict of interest: The authors declare no conflicts of interest.
TOCILIZUMAB: IS OUT OF SIGHT REALLY OUT OF MIND?
Salema Khalid 1 , Richard Smith 1 , and Zoe Cole 1 1 Rheumatology, Salisbury District Hospital, Salisbury, United Kingdom Introduction: Giant cell arteritis (GCA) is the most common form of vasculitis in adults with visual complications, in particular loss of vision, constituting the most feared manifestation. Tocilizumab (TCZ), an IL-6 receptor blocker, has been shown to induce lasting remission. However, the optimal duration of treatment with tocilizumab and risk of relapse once treatment is stopped, is currently unknown. We present an unusual case of a patient with GCA who developed visual loss after stopping a three year course of tocilizumabfor surgical indications. Case description: A 73-year-old lady presented to her GP in 2011 with headache and lower limb stiffness. At that time CRP was greater than 200 and ESR was 126. The GP commenced her on high dose prednisolone with an excellent response. A temporal artery biopsy was not done. She was then referred 14 months later to the rheumatology clinic due to bilateral hip pain and difficulty weaning off steroids, with an increase in inflammatory markers and return of symptoms, upon dose reduction. She was still on 30mg prednisolone at the time of referral. Methotrexate was introduced as a steroid sparing agent, but was stopped a few months later due to side effects. In 2012, while on prednisolone, she developed avascular necrosis of both hips requiring bilateral total hip replacements. An IFR wasgrantedtostartTCZ in2014.She remained well onit withgood clinical and serological response and eventually came off steroids completely in 2016. In July 2017, TCZ was stopped for aortic valve replacement for 4 months. This was then restarted at the beginning of December 2017. In February 2018, she developed frontal headaches and PMR-like symptoms. CRP was 2 and ESR 27 at this time. She was commenced on 15 mg daily of prednisolone and TCZ was continued at 8mg/kg. Unfortunately, a few days after her TCZ infusion, she was admitted to hospital with anterior ischaemic optic neuropathy(AION)in the left eye, resulting in partial blindness. Inflammatory markers were found to be completely normal. Intravenous methyl prednisolone was commenced. The patient was referred to a tertiary referral centre and TCZ 162 mg subcutaneously weekly was commenced in combination with leflunomide while tapering the dose of prednisolone. She is currently well with no new visual symptoms. Discussion: This is an unusual case as the patient developed AION whilst on 15 mg of prednisolone following cessation and then re-institution of tocilizumab. The GiACTA trial showed that treatment with TCZ, while extremely efficacious, did not prevent disease flares in all patients, with 24% of patients in TCZ groups experiencing at least 1 or more disease flares. The trial proposed that the flares might be attributable to Th-1 cells, which are not affected directly by IL-6 receptor blockade, and may play an important role in somepatients with GCA. Recently, the long-term safety and maintenance of efficacy in GCA patients was assessed in a 2-year extension of the GiACTA trial. Among the 81 patients in the once weekly TCZ arm, who were in clinical remission at week 52, 38 (47%) maintained clinical remission through part 2. However, only 25 of these 38 patients (66%) were treatment-free (no TCZ and no glucocorticoid treatment) at the end of the trial. Similarly, the risk of relapse after discontinuation of TCZ in GCA was assessed in a study by Adler et al. 17 of 20 patients randomised to the TCZ treatment arm were in remission after 12 months. Only half stayed in clinical remission after cessation of TCZ. No clinical or laboratory marker was found to be a reliable predictor of relapse. These two studies show that the odds of relapse after discontinuation are very high, as seen in our case. Furthermore, Adler et al reported that the mean time to relapse was 6.3 months. This shows that the risk of relapse is highest in the first few months,as is the case inour patient. Key learning points: The optimal strategies for monitoring disease progress in GCA remain uncertain, and currently rely on assessing clinical features and measuring inflammatory markers. However, this has become even more challenging with the use of TCZ, which suppresses the acute phase response via IL-6 receptor blockade. CRP and ESR remain low in nearly all TCZ-treated patients who experience disease flares. This underlines the importance of clinical assessment, particularly poignant history-taking and clinical experience in assessing whether GCA activity might be present. Clinicians should have a very low threshold for suspecting a flare-up, as even the mildest of symptoms could be a harbinger of a full blown flare. As discussed above, studies have shown that effectively half the patients relapse after TCZ is discontinued and most do so within the first few months. This emphasizes the need for careful clinical observation during this time and immediate resumption of treatment in those with new symptoms. Furthermore, it raises the possibility that patients may need to be on TCZ long term and in certain cases indefinitely, given the very high risk of recurrence once the patient is off the drug. Further research and deeper understanding is needed of the pathways that lead to a flare of GCA while on optimal treatment. Finally, this case underscores the dire need for advances in the development of clinically useful biomarkers to help monitor disease activity and predict relapses in patients on TCZ. This case brings to light the fact that AION is possible following cessation and re-institution of tocilizumab.It isaxiomatic thatclinicians keep aclose eye on patients stopping TCZ after the NICE guideline 12 month recommended course. Conflict of interest: The authors declare no conflicts of interest.
i14 27 September 2019 ORAL PRESENTATIONS
